PO.MCB09.01 · 分子与细胞生物学

非转移性与转移性乳腺癌细胞及脂滴蛋白质组的比较

Comparison of non-metastatic and metastatic breast cancer cell and lipid droplet proteomes

编号 2019 展板 12 时间 4/20 09:00–12:00 区域 Section 24 主讲 Chaylen Andolino, PhD
分会场 Metabolic Regulation in Breast and Gynecologic Cancers
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Chaylen Andolino, Kimberly K. Buhman, Dorothy Teegarden

Nutrition Science, Purdue University, West Lafayette, IN

摘要 Abstract

中文摘要
转移性乳腺癌细胞常在胞质脂滴(LD)中对中性脂质(如三酰甘油,TAG)的细胞储存增加。尽管LD积累与癌症侵袭性增强相关,但这些细胞器在促成转移性疾病中的作用仍不明确。除了在LD核心储存TAG外,磷脂单层还装饰有多种蛋白质。鉴于LD相关蛋白反映了该细胞器在特定生理环境下的功能,我们对人转移性与非转移性乳腺癌细胞系的LD蛋白质组进行了表征,以评估可能与LD相关联进而促进转移的候选蛋白通路。 对通过蔗糖密度梯度超速离心从非转移性MCF10CA1h(LD较少)和转移性MCF10CA1a(LD较多)细胞系分离的LD进行了非靶向鸟枪法蛋白质组学分析。利用MaxQuant、MassDynamics、Metascape和STRING对LD蛋白质组以及每种细胞系全细胞裂解物(WCL)的蛋白质组进行了比较。 我们发现,与非转移性细胞的LD相比,转移性细胞的LD高度富集与LD组织和蛋白质定位相关的蛋白质。有趣的是,参与NFκB隔离的蛋白质是转移性细胞LD中相较非转移性细胞富集程度最高的脂质相关蛋白类别。此外,NFκB在两种细胞系的WCL中富集程度相似;然而,仅在转移性细胞的分离LD组分中被检测到。另外,LD分解代谢的负调控因子——缺氧诱导脂滴相关蛋白(HILPDA),仅在转移性细胞的LD组分中被检测到。鉴于NFκB和HILPDA在肿瘤进展和治疗抵抗中的作用,本研究结果提供了可检验的假说,有助于阐明LD如何促成乳腺癌转移。例如,LD可能作为信号传导的支架,以协调脂质代谢和转移过程,或作为一个应激适应平台,在缺氧诱导因子(HIF)激活下实现快速的脂质介导信号传导。此外,鉴于HILPDA稳定储存类花生酸合成前体的LD,而类花生酸进而调节NFκB活性和随后的炎症反应,这些介质之间的相互作用可能整合成一个代谢-炎症轴,以促进肿瘤进展和免疫逃逸。 总之,我们的结果表明,虽然源自同一亲本系的非转移性与转移性乳腺细胞的全局蛋白质组相似,但与LD相关的蛋白质差异很大。本研究提供了一份候选蛋白清单,可供进一步实验以确定它们在维持LD积累和转移进展中的作用。
查看英文原文 English abstract
Metastatic breast cancer cells often have increased cellular storage of neutral lipids, such as triacylglycerol (TAG), in cytoplasmic lipid droplets (LDs). Although LD accumulation is associated with increased cancer aggressiveness, the role of these organelles in contributing to metastatic disease remains unclear. Aside from TAG storage within the core of the LD, the phospholipid monolayer is also decorated with a variety of proteins. Given that LD-associated proteins reflect the organelle's function within a given physiological context, we characterized the proteome of LDs from a human metastatic compared to non-metastatic breast cancer cell line to assess potential candidate protein pathways that may associate with LDs to promote metastasis. Untargeted shotgun proteomics of LDs isolated via sucrose density gradient ultracentrifugation from non-metastatic MCF10CA1h (less LDs) and metastatic MCF10CA1a (more LDs) cell lines was performed. The LD proteomes, as well as the proteome of each cell line's whole cell lysate (WCL), were compared utilizing MaxQuant, MassDynamics, Metascape, and STRING. We identified that LDs from metastatic cells are highly enriched in proteins related to LD organization and protein localization compared to LDs from non-metastatic cells. Interestingly, proteins involved in the sequestering of NFκB were the most highly enriched lipid-related protein category in LDs of metastatic compared to non-metastatic cells. Further, NFκB was similarly enriched in the WCLs of both cell lines; however, was only identified in the isolated LD fraction from metastatic cells. Additionally, the negative regulator of LD catabolism, hypoxia inducible lipid droplet associated protein (HILPDA), was only identified in the metastatic cell LD fractions. Given the role of NFκB and HILPDA in tumor progression and therapy resistance, results from this study provide testable hypotheses that can elucidate how LDs contribute to breast cancer metastasis. For example, LDs may act as scaffolds for signaling to coordinate lipid metabolism and metastatic processes or as a stress-adaptive platform to enable rapid lipid-mediated signaling under hypoxia inducible factor (HIF) activation. Additionally, given that HILPDA stabilizes LDs which store precursors for eicosanoid synthesis, which in turn modulate NFκB activity and subsequent inflammatory response, the interactions of these mediators may integrate into a metabolic-inflammatory axis to promote tumor progression and immune evasion. Together, our results indicate that though the global proteome of non-metastatic and metastatic breast cells derived from the same parental line are similar, the proteins associated with LDs vary greatly. This study provides a list of candidate proteins for additional experimentation to determine their role in sustaining LD accumulation and metastatic progression.
利益披露 Disclosure
C. Andolino, None.. K. K. Buhman, None.. D. Teegarden, None.

← 返回 AACR 2026 检索